Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etonogestrel implant - Merck & Co

Next Previous
Drug Profile

Etonogestrel implant - Merck & Co

Alternative Names: 3-Keto-desogestrel; 3-Keto-DOG; 3-Oxodesogestrel; Etonogestrel extended-release subdermal implant; Implanon; Implanon NXT; MK-8415; NEXPLANON; Nexplanon; Org 32222; ORG-3236; SCH900415

Latest Information Update: 29 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organon
  • Developer Merck & Co; Organon; Pharmaco (NZ); Schering-Plough
  • Class Hormonal contraceptives; Norpregnanes; Phenanthrenes; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 29 Jan 2026 Etonogestrel implant is still in phase III trial for Pregnancy (Prevention) in USA and Puerto Rico (Intradermal) (NCT04626596)
  • 17 Jan 2026 The US FDA approves sNDA for extedend use of etonogestrel implant for Pregnancy (prevention) in the US
  • 30 Dec 2024 Merck completes the phase III trial for Pregnancy (Prevention) in USA and Puerto Rico (Intradermal) (NCT04626596)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top